SCHEMBL4121094

SCHEMBL4121094

COc1ccc2nc(C#N)c3c(C)nc(-c4ccc(Cl)cc4Cl)n3c2n1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 20/20 0.78
PDE2A O00408 17/20 0.78
PDE7A Q13946 3/20 0.66
PDE6D O43924 2/20 0.53
PDE6A P16499 2/20 0.53
PDE6G P18545 2/20 0.53
PDE6B P35913 2/20 0.53
PDE6C P51160 2/20 0.53
PDE6H Q13956 2/20 0.53
PDE4A P27815 1/20 0.53
PDE4B Q07343 1/20 0.53
PDE4C Q08493 1/20 0.53
PDE4D Q08499 1/20 0.53
PDE3B Q13370 1/20 0.53
PDE3A Q14432 1/20 0.53
PDE5A O76074 1/20 0.50
PDE11A Q9HCR9 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4119110 0.92 PDE10A (0.78) PDE10APDE2APDE7APDE6DPDE6A
SCHEMBL4124326 0.88 PDE10A (0.83) PDE10APDE2APDE7APDE6DPDE6A
SCHEMBL4126852 0.88 PDE10A (1.00) PDE10APDE2APDE7APDE6DPDE6A
SCHEMBL4128258 0.82 PDE10A (0.69) PDE10APDE2APDE7APDE3APDE5A
SCHEMBL4129550 0.81 PDE10A (0.80) PDE10APDE2APDE7APDE6DPDE6A
SCHEMBL4117092 0.79 PDE10A (1.00) PDE10APDE2APDE7APDE6DPDE6A
SCHEMBL4118549 0.79 PDE10A (0.79) PDE10APDE2APDE7APDE6DPDE6A
SCHEMBL4121320 0.79 PDE10A (0.79) PDE10APDE2APDE7APDE3APDE5A
SCHEMBL4127160 0.78 PDE10A (0.78) PDE10APDE2APDE7APDE3APDE5A
SCHEMBL4128598 0.78 PDE10A (0.77) PDE10APDE2APDE7APDE6DPDE6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009070583-A1 PYRIDO[3,2-E]PYRAZINES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO claimed
US-20090143361-A1 Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 ELBION GMBH (DE) 2009-06-04 US claimed
US-20090143361-A1 Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 ELBION GMBH (DE) 2009-06-04 US disclosed
US-20090143361-A1 Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 ELBION GMBH (DE) 2009-06-04 US disclosed
US-20090143361-A1 Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143361-A1 Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 PDE12, PDE5A, PDE3A PDE10A 10/4885PDE2A 4/4885PDE7A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.